Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.74 |
| ▸ | PPARG | P37231 | 17/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599062 | 0.86 | PPARG (0.85) | PPARAPPARG | |
| Muraglitazar SCHEMBL676469 | 0.85 | PPARA (1.00) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL6060716 | 0.84 | PPARA (0.81) | PPARAPPARG | |
| SCHEMBL6342308 | 0.84 | PPARA (0.87) | PPARAPPARGCYP3A4CYP2C9KCNH2 | |
| SCHEMBL13722049 | 0.82 | PPARA (0.93) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13718146 | 0.82 | PPARA (0.93) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13762778 | 0.81 | PPARA (0.76) | PPARAPPARG | |
| SCHEMBL13721568 | 0.81 | PPARG (0.73) | PPARAPPARG | |
| SCHEMBL6073227 | 0.80 | PPARA (0.90) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL14445739 | 0.80 | PPARG (0.53) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | PPARA 24/4885PPARG 65/4885CYP3A4 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.